Nurix Therapeutics Stock Earnings Per Share
| NRIX Stock | USD 21.82 0.23 1.04% |
Nurix Therapeutics fundamentals help investors to digest information that contributes to Nurix Therapeutics' financial success or failures. It also enables traders to predict the movement of Nurix Stock. The fundamental analysis module provides a way to measure Nurix Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nurix Therapeutics stock.
Nurix | Earnings Per Share |
Nurix Therapeutics Company Earnings Per Share Analysis
Nurix Therapeutics' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Nurix Therapeutics Earnings Per Share | (2.90) X |
Most of Nurix Therapeutics' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nurix Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Nurix Earnings Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Nurix Therapeutics is extremely important. It helps to project a fair market value of Nurix Stock properly, considering its historical fundamentals such as Earnings Per Share. Since Nurix Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Nurix Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Nurix Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
Nurix Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
According to the company disclosure, Nurix Therapeutics has an Earnings Per Share of -2.9 times. This is 134.65% lower than that of the Biotechnology sector and 39.46% lower than that of the Health Care industry. The earnings per share for all United States stocks is 192.95% higher than that of the company.
Nurix Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nurix Therapeutics' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nurix Therapeutics could also be used in its relative valuation, which is a method of valuing Nurix Therapeutics by comparing valuation metrics of similar companies.Nurix Therapeutics is currently under evaluation in earnings per share category among its peers.
Nurix Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Nurix Therapeutics from analyzing Nurix Therapeutics' financial statements. These drivers represent accounts that assess Nurix Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Nurix Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 668.0M | 1.2B | 602.3M | 338.0M | 304.2M | 518.5M | |
| Enterprise Value | 548.6M | 1.2B | 549.7M | 314.0M | 282.6M | 475.4M |
Nurix Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Nurix Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Nurix Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Nurix Fundamentals
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (4.34) % | ||||
| Current Valuation | 1.14 B | ||||
| Shares Outstanding | 70.84 M | ||||
| Shares Owned By Insiders | 1.45 % | ||||
| Shares Owned By Institutions | 98.26 % | ||||
| Number Of Shares Shorted | 9.46 M | ||||
| Price To Book | 4.14 X | ||||
| Price To Sales | 27.39 X | ||||
| Revenue | 76.99 M | ||||
| Gross Profit | (145.87 M) | ||||
| EBITDA | (141.41 M) | ||||
| Net Income | (143.95 M) | ||||
| Cash And Equivalents | 344.48 M | ||||
| Cash Per Share | 7.31 X | ||||
| Total Debt | 30.61 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 5.26 X | ||||
| Book Value Per Share | 5.62 X | ||||
| Cash Flow From Operations | (81.36 M) | ||||
| Short Ratio | 11.33 X | ||||
| Earnings Per Share | (2.90) X | ||||
| Target Price | 31.2 | ||||
| Number Of Employees | 284 | ||||
| Beta | 2.2 | ||||
| Market Capitalization | 1.55 B | ||||
| Total Asset | 355.6 M | ||||
| Retained Earnings | (545.2 M) | ||||
| Working Capital | 208.54 M | ||||
| Net Asset | 355.6 M |
About Nurix Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nurix Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nurix Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nurix Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Nurix Stock Analysis
When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.